CARLSBAD, Calif. , Aug. 21, 2024 /PRNewswire/ -- Today, Limmi – an AI startup dedicated to transforming patient outcomes by rapidly discovering hidden patterns in life sciences data – announced that Professor of Urology at UT Health San Antonio, Dr.
Michael Liss , M.D., Ph.
D., has joined the company's Advisory Board. Dr.
Liss brings a wealth of experience and expertise, particularly in the field of early cancer screening and innovative clinical trials. Dr. Liss is widely recognized for his work in early cancer detection and treatment and has led numerous clinical trials that have significantly advanced the treatment of urologic cancers.
Currently, Dr. Liss is the site principal investigator for SWOG, formerly the Southwest Oncology Group, one of the world's largest cooperative clinical trial groups. He also serves as the medical director of clinical research at University Health.
Liss is also an active member of the cancer center's genetics and high-risk cancer screening clinic, focusing on patients at high risk for kidney and prostate cancer. His dedication to improving patient outcomes through innovative research aligns perfectly with Limmi's mission. Limmi utilizes cutting-edge AI and deep learning methodologies on a platform built specifically for healthcare and biotech, offering their customers real-time predictions and insights to patients, radically changing the way their customers manage healthcare operations and patient health management.
"We are thrilled to have.